Ted Slocomb

Ted Slocomb is the Vice President, Global Market Access for Astellas Gene Therapies with responsibility for leading market access and value demonstration for the Astellas gene therapy pipeline. He joined Astellas Gene Therapies (formerly Audentes Therapeutics) in January 2015, and has over a decade of experience in developing and executing launch strategies specifically for ultra-rare disease biopharmaceuticals, including high value gene and cell therapies.

Prior to Audentes, Ted held roles of increasing responsibility in US and global marketing, new product planning, corporate development and venture capital at firms such as Amylin Pharmaceuticals (global commercial leader, MYALEPTÒ/metreleptin for injection, obesity franchise commercial lead), Bear Stearns Health Innoventures, Fate Therapeutics, Johnson & Johnson and BASF Pharma. He is a former co-chair of the US Market Access & Value Committee of the Alliance for Regenerative Medicine (ARM).

Ted earned his B.A. in Genetics from the University of California, Berkeley and his M.B.A. in Finance from the Stern School of Business at New York University.